The Institute has given us a kind of petting zoo of emotional therapeutics.
Given the notion that the FR has also been recognized as an important target for (image guided) delivery of therapeutics, FR-based PET imaging could be exploited to select patients who would benefit from FR mediated targeting of activated macrophages by antifolates [ 12].
In the development of such therapeutics for IPF, our PET findings may play a role by potentially offering early disease detection and monitoring of therapeutic response to treatment.
It is Inhale Therapeutic Systems, not Inhaled Therapeutics System.
As shown in Fig. 1b, nanomaterials as carriers are capable of accommodating various materials based on the final application of the delivery system, from targeting agents, such as forlic acid (FA) to diagnostic theranostic agents for use in MRI, computed tomography (CT), positron emission tomography-computed tomography (PET-CT), sensors and so on, and therapeutics.
Combined, these and many other findings have led to the use of FDG-PET as a biomarker for tracking AD-related metabolic impairments and a prediction that FDG-PET will help increase the clinical efficacy of therapeutics targeting brain metabolism abnormalities [ 7].
In order to guide the use of FDG-PET in the clinical development of novel anti-cancer therapeutics and further understand drug-tumor-imaging relationships, we ran a series of cell-based 18 F-FDG uptake assays in vitro.
This indicates that Zr-labeled immuno-PET is an attractive method to evaluate Met-targeted therapeutics.
In view of selecting patients that could benefit from potential CB1R-targeted therapy approaches or investigating the efficacy of newly developed CB1R-based therapeutics in vivo in a (pre clinical setting, imaging of CB1R with PET might help to select those patients benefitting from such a treatment.
Nevertheless, the Aβ PET ligands have a clear role in AD diagnosis and can be used as target engagement biomarkers for some potential therapeutics, including antibodies [ 100, 101].
